Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. Haleon plc(LSE:HLN) operates independently of GSK plc as of July 18, 2022.
IPO Year: 2022
Exchange: NYSE
Website: https://www.haleon.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/5/2024 | Buy | Berenberg | |
4/17/2024 | Buy | HSBC Securities | |
12/11/2023 | Buy | Jefferies | |
11/1/2023 | $9.00 | Overweight | Morgan Stanley |
5/24/2023 | Hold | Stifel | |
4/6/2023 | $10.00 | Hold → Buy | Argus |
4/4/2023 | Outperform | Bernstein | |
12/7/2022 | Equal Weight → Overweight | Barclays | |
9/28/2022 | Hold | Argus |
On Wednesday, Haleon plc (NYSE:HLN) agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY) for 500 million pounds (around $632 million). The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets. The 500 million pound consideration is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026. The transaction
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United StatesAcquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC businessIn recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé IndiaDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its subsidiary Dr. Re
Sanofi SA (NASDAQ:SNY) is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considering a potential public listing. Potential suitors must submit first-round bids by mid-July, Bloomberg reports. Advent International and France’s PAI Partners both expressed interest in acquiring the division, which includes over-the-counter products such as Phytoxil cough syrups and Icy Hot pain relief gels. PAI is the sole French bidder and might need to find partners to manage the transaction’s scale. Other major firms considering bids include Blackstone Inc (NYSE:BX), Clayton Dubilier & Rice, CVC Capital Partners Plc, and TPG Inc.
GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon. Following the settlement of the placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon. See Also: Colgate-Palmolive Has Strong Brand-Building And Analytics-Driven Marketing Strategy, Says Analyst Following the demerger and premium listing of Haleon in July 2022, GSK initially retained a 12.94% stake in Haleon. As a result of the disposals, GSK has sold 1.19 billion shares in Haleon for cumulative gross proceeds. In October, GSK raised $1.1 billion
https://www.haleon.com/news/press-releases/corporate/2024/appointment-of-dawn-allen-as-chief-financial-officer
Argus Research analyst Taylor Conrad maintains Haleon (NYSE:HLN) with a Buy and maintains $10 price target.
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC business In recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé India Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its sub
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
The leader in cold sore relief will shine a light on the condition, rewarding one cold sore sufferer with the limited edition, sparkling accessory. WARREN, N.J., Feb. 6, 2024 /PRNewswire/ -- Abreva is encouraging consumers to rock their cold sores with confidence, unveiling a highly covetable, one-of-a-kind pair of diamond lips. The bejeweled piece is fashioned to destigmatize a condition that many are ashamed to discuss, let alone flaunt. In fact, 2/3 of young cold sore sufferers say their self-esteem and confidence is shaken when a cold sore strikes1. The jaw-dropping 16 car
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i
A third study from the COSMOS trial, COSMOS-Clinic, demonstrates consistent findings that taking Centrum Silver multivitamin daily benefits memory among older adults. WARREN, N.J., Jan. 24, 2024 /PRNewswire/ -- New study results from the COSMOS trial offers additional evidence regarding the benefit of Centrum Silver multivitamins on cognitive health in older adults. The third independent cognition trial to measure cognitive function and memory in older adults echoed previous findings of COSMOS-Mind and COSMOS-Web which all indicate that daily use of Centrum Silver versus placebo resulted in significant improvements in performance on tests measuring memory.
The Official TUMS Bag is Available on Amazon and nikolasbentelstudio.com – Hurry, Before They Sell Out! WARREN, N.J., Dec. 8, 2023 /PRNewswire/ -- At a time when foodie fashion – from pasta handbags to cheeseburger dresses, fried chicken footwear and beyond – has been making a delicious statement, TUMS, America's #1 Antacid brand, is dipping into culinary couture to bring heartburn relief to food fans in a fashionable way. In partnership with New York artist and designer, Nik Bentel, TUMS has cooked up its first-ever limited edition bag accessory: The TUMS Bag. The bag is a love letter to those who want to wear their foodie heart (quite literally) on their sleeves, blending the essence of
Phase two of Economist Impact's Health Inclusivity Index, supported by Haleon, measures experience of health inclusion across 42,000 people in 40 countriesHealth inclusivity scores fall worldwide with addition of lived experience data, exposing glaring policy-practice gap in wealthy countries66% of survey respondents experience barriers to health inclusion, with the most vulnerable worst affected Index reveals stark generational divide with Gen Z and Millennials experiencing greater barriers to access and higher levels of discrimination LONDON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- More than three in five people worldwide experience health exclusion, with vulnerable and younger popu
The second phase of the index, supported by Haleon, assesses governments' efforts across 40 countries to ensure that good health is accessible to all individuals LONDON, Nov. 20, 2023 /PRNewswire/ -- Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, today launched phase two of the Health Inclusivity Index, supported by Haleon (NYSE:HLN), a global leader in consumer health. This phase's results show health inclusivity falling worldwide, and notably Britain falling from its top spot in phase one. The index measures
Latest edition of Haleon Pain Index finds half (49%) of people in pain feel stigmatised[1][2]42% regularly feel lonely due to their pain, and one third feel serious loneliness (based on UCLA loneliness scale)[3]32% of people living in pain fear they will be judgedWomen, people of colour and the LGBQ+ community are worst affectedGen Z more likely to feel unheard than Baby Boomers LONDON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- A new study of 18,097 people across 18 countries has discovered that society has grown less tolerant of people in pain, despite the effects of COVID-19 boosting global health awareness. The fifth edition of the Haleon Pain Index (HPI)[1], conducted by consumer health com
Leader in joint pain relief stands with caregivers help recognize their value and provide pain relief and movement resources. WARREN, N.J., May 16, 2023 /PRNewswire/ -- More than 53 million Americans provide care to family members or loved ones,1 but an overwhelming 4 out of 5 Americans say that pain has affected their caregiving abilities.2 Caregivers dedicate so much time and energy – both emotionally and physically – to taking care of others, and the day-to-day realities of caregiving can involve a lot of physical labor and heavy lifting that may lead to aches and pains. In effort to help caregivers combat pain, Voltaren Arthritis Pain Gel is partnering with fitness instructor and TV per
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i
Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities. The exchange offers referred to herein are being made solely pursuant to the Prospectus and related documents. The exchange offers referred to herein are not being made to holders of securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. LONDON, Oct. 31, 2022 /PRNewswire/ -- Haleon plc ("Haleon
Berenberg initiated coverage of Haleon plc with a rating of Buy
HSBC Securities initiated coverage of Haleon plc with a rating of Buy
Jefferies resumed coverage of Haleon plc with a rating of Buy
Morgan Stanley initiated coverage of Haleon plc with a rating of Overweight and set a new price target of $9.00
Stifel initiated coverage of Haleon plc with a rating of Hold
Argus upgraded Haleon plc from Hold to Buy and set a new price target of $10.00
Bernstein initiated coverage of Haleon plc with a rating of Outperform
Barclays upgraded Haleon plc from Equal Weight to Overweight
Argus initiated coverage of Haleon plc with a rating of Hold
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
SD - Haleon plc (0001900304) (Filer)
20-F/A - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)